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| INTRODUCTION
Hepatitis C virus (HCV) infects over 71 million people worldwide and is a significant etiological agent in the development of chronic liver disease.
1 HCV establishes chronic infection in the majority of patients, while only a minority of patients (15%-25%) with acute HCV spontaneously clear the virus. Long-term chronic HCV infection results in persistent liver injury that can progress to cirrhosis after 15-20 years and risks of complications of end-stage liver disease such as decompensated liver failure, hepatocellular carcinoma and death. 2 Human immunodeficiency virus (HIV) coinfection with HCV occurs in approximately 30% of patients owing to similar transmission routes and has been associated with accelerated liver fibrosis progression and more frequent liver-related complications, such as decompensation. 3 In the postantiretroviral era, liver disease is now the second leading cause of non-AIDS-related mortality in HIV patients and therefore represents a significant health issue in these individuals. 3 The development of direct-acting antiviral agents (DAAs) that tar- 
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The aims of this study were to characterize the effect of viral antigen removal on peripheral ISG and interferon-effector gene (IEG) expression and circulating chemokines/cytokines in participants enrolled in the A5327 study who were receiving sofosbuvir (SOF) and ribavirin (RBV) for the treatment of acute HCV infection. Furthermore, we planned to assess levels of ISGs/IEGs or chemokines/cytokines for any association with viral eradication and treatment response. In the parent study, only 58% of individuals achieved an SVR, with the remaining patients relapsing following the completion of IFN-free therapy, representing a unique and well-characterized cohort to study differences in immune profiles between patients who ultimately clear virus and those who relapse following DAA therapy in the context of acute HCV infection.
| MATERIALS AND METHODS

| Patients and study design
A5327 was an open-label multicenter clinical trial to determine the safety and efficacy of IFN-free DAA therapy in HIV-1 subjects with confirmed acute HCV infection (NCT02128217). This study focuses on cohort one of this trial, where patients were treated with sofosbuvir plus weight-based ribavirin for 12 weeks. Key inclusion/exclusion criteria for entry into this study are summarized in Table S1 (see NCT02128217 for additional detail). All patients were HIV-1 positive on antiretroviral therapy (ART) and demonstrated HIV viral suppression throughout the study.
All subjects consented to collection of serum and peripheral blood mononuclear cells (PBMCs) at baseline, on-treatment week 4 (TW4), end of treatment (EOT) and at post-treatment week 12 (PTW12).
Immune profiling was completed at each time point. Per the parent protocol, SVR was defined as HCV RNA less than the lower limit of quantification (<LLoQ) target not detected (TND) at PTW12, and relapse was defined as HCV RNA undetectable (<LLoQ and TND) at EOT but quantifiable HCV RNA (≥LLoQ) at any time during post-treatment follow-up. Participants achieving SVR will be referred to as responders in this study. The study was approved by each local institutional review board, and all participants provided written consent. The study was conducted according to the Declaration of Helsinki. and chemokine (C-C motif) ligand five (RANTES) was measured using the human RANTES ELISA kit (eBioscience, San Diego, CA, USA).
| IFNL3 rs12979860 genotyping
| Statistical analyses
Change in immune profiles from baseline to each study time point was calculated. Categorical data are presented as frequencies, and continuous data are presented as medians with interquartile ranges.
The chi-squared and Fisher's exact t tests were used to compare categorical data, and continuous data were compared with the MannWhitney U test and the Wilcoxon signed-rank test for unpaired and paired samples, respectively. GraphPad Prism v6 (GraphPad Software, Inc., La Jolla, CA) and STATA v11 were used to compare baseline demographics and levels of chemokines/cytokines. Peripheral gene expression data were generated using the nSolver software (NanoString Technologies), and R Studio v0.99.902 (RStudio, Inc., Boston, MA) and STATA v11 (StataCorp LP, College Station, TX) were used to determine differentially expressed genes in responders vs relapse. A P-value of <.05 was considered significant, and a P-value with Bonferroni correction was set at .001.
| RESULTS
| Patients
Fourteen of the 17 patients enrolled in the original parent study were included in this substudy. Three patients were excluded for the following reasons: two patients were found to have detectable HCV RNA at screening but at baseline the HCV RNA was subsequently found to be undetectable or extremely low at baseline (<100 IU/mL) and therefore these patients were excluded as they were felt likely to have different immune profiles to the remaining patients with high HCV RNA levels; the third patient did not have stored paired PBMC and plasma samples available for all study time points.
The baseline demographics and patient characteristics are presented in Table 1 . In brief, all patients were male, with a median age of 46 years, and predominantly infected with HCV genotype one (93%). The majority of patients had the non-C/C IFNL3 genotype (8% C/C, 71% C/T and 21% T/T). Median baseline HCV RNA level was 6.39 log 10 IU/mL. All patients were receiving ART with suppression of HIV RNA <50 copies/mL, and the median CD4 count was 452 cells/mm 3 . There were no significant differences in baseline demographics and patient characteristics between responders and relapsers (Table 1 ).
In the parent study, the overall SVR rate for cohort one was only 58% (10 of 17), and all virologic failures were due to virologic relapse.
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In this substudy, two of the 14 patients had high HCV RNA levels at baseline, defined as HCV RNA levels >6 000 000 IU/mL. At TW4, 86%
had HCV RNA levels below the LLoD, and all patients had undetectable HCV RNA levels at EOT (Figure 1 ). The SVR rate was similar to the overall study (57%, eight of 14) (Figure 1 ). As observed in the parent study, all treatment failures were virologic relapse and no patient experienced viral breakthrough or viral nonresponse. 
| Gene expression
We determined the gene expression profiles of a panel of biologically relevant ISGs (n = 45) and IEGs (n = 9) previously reported to be important in HCV [4] [5] [6] 17, 18 in PBMCs at baseline, TW4, EOT and PTW12.
Of the 14 patients from this substudy, 13 were included in this gene expression analysis; one patient was excluded as their baseline RNA sample failed stringent NanoString quality control parameters. 
| Baseline ISG/IEG expression profiles
| On-treatment and post-treatment ISG/IEG expression profiles
Treatment week 4 (TW4)
At TW4, the majority of ISGs were downregulated (37 of 47) in the setting of on-treatment viral clearance in all patients, whereas only three of the nine IEGs were downregulated at TW4 (4 upregulated, two unchanged). However, only five genes (all ISGs) demonstrated >1.5-fold differential expression compared to baseline levels with a P-value <.05, including CXCL10, CXCL11, IFI44L, IFIT1 and IFIT3 ( Figure 3 , Table S2 ).
In addition, 10 genes were upregulated at TW4, but none were differentially expressed >1.5-fold above baseline levels ( Figure 3 , Table   S2 ). When stratified according to treatment outcome, only two genes were found to be differentially expressed >1.5-fold among responders and relapsers at TW4, including NOS2a (downregulated in relapsers)
and GUCY1B3 (upregulated in relapsers) (all P-values <.05) ( Table S3) .
End of Treatment (EOT)
At EOT, the majority of ISGs were downregulated (40 of 47), 6 of which were >1.5-fold differentially expressed with a Pvalue <.05 ( Figure 3 , Table S2 ). Only four of the nine IEGs were downregulated, but none were differentially expressed >1.5-fold above baseline. Of the remaining IEGs, two IEGs were unchanged and three were upregulated but were <1.5-fold above baseline. CXCL11  CXCL10  GBP1  STAT1  IFI35  OAS1  DDX58  IRF2  RNaseL  HERC6  CCl2  DDX60  IFIT1  IFIT3  OAS2  ISG15  EIF2AK2  IFI44  IFI44L  HERC5  RSAD2  MX1  MX2  OASL  IFI6  PLSCR1  MS4A4A  IFI27  ALG10  SLC27A2  USP18  CCL4  IFITM3  IRF1  IFIT2  IFIT5  TRIM14  ADAR  IFIH1  IRF9  MAP3K14  MOV10  PPP3CB  IRF7  HELZ2  NOS2a  GCKR  DDIT4  ISG20  IFITM1  DPP4  BCHE  NT5C3  GUCY1B3  IFITM2 In addition, the gene expression levels of the ISGs DDIT4, IFI27,
IFI44, IFIT2 and RSAD2, as well as the IEGs GCKR and GUCY1B3,
were differentially expressed >1.5-fold between relapsers compared to responders (P < .05) (Table S3) .
Post-Treatment Week 12 (PTW12)
In the context of viral relapse, gene expression profiles differed in responders compared to relapsers, with upregulation of 32 of the 47
ISGs in relapsers ( Figure 3 , Table S2 ), 11 of which were differentially TW4  TW4  TW4  TW4  TW4  TW4  TW4  TW4  TW4  TW4  TW4  TW4  TW4  EOT  EOT  EOT  EOT  EOT  EOT  EOT  EOT  EOT  EOT  EOT  EOT  EOT  PTW12  PTW12  PTW12  PTW12  PTW12  PTW12  PTW12  PTW12  PTW12  PTW12  PTW12  PTW12  PTW12   Treatment outcome  Time point   CXCL11  CXCL10  GBP1  STAT1  IFITM3  IFIT2  IFI27  HERC5  EIF2AK2  IFI44  IFI44L  MX1  RSAD2  ISG15  USP18  IFI35  DDX60  IFIT1  IFIT3  OAS2  OAS1  DDX58  IRF2  RNaseL  IFIH1  ADAR  IRF9  MAP3K14  MOV10  IFI6  IRF7  MX2  HELZ2  PLSCR1  OASL  IFIT5  IFITM1  HERC6  DPP4  TRIM14  PPP3CB  CCl2  ALG10  SLC27A2  IFITM2  MS4A4A  DDIT4  MYST1  CCL4  IRF1  NOS2a  BCHE  GCKR  NT5C3  GUCY1B3  ISG20 relative row min r ow max SVR Relapser expressed more than 1.5-fold with a P-value <.05. No IEGs were found to have differential expression according to treatment outcome at PTW12 (Figure 3 , Table S3 ).
| Changes in plasma levels of chemokines/ cytokines with DAA treatment
| Baseline
We determined the levels of a panel of circulating chemokines and cytokines from plasma samples at each time point reported to be associated with treatment response in chronic HCV infection. Figure 4 shows the median levels for six of the 14 quanti- 
| On-treatment and post-treatment
IFNα levels
Interestingly, although levels of IFNα did not significantly change during treatment in responders, there was a trend towards increased IFNα at TW4 in responders, and levels were significantly higher in responders at EOT and PTW12 compared to relapsers (Figure 4 ), suggesting impaired IFNα production or secretion in patients that subsequently relapse with SOF+RBV.
IP-10, CXCL11, MIP-1β, IL-18 and IL-8 levels
IP-10 levels were significantly lower at TW4 and EOT compared to baseline in both responders and relapsers (Figure 4 ). IP-10 levels remained low at PTW12 in responders, but returned to pretreatment levels in the context of relapse (Figure 4) . Similarly, CXCL11 levels were significantly lower at TW4 and EOT compared to baseline in responders and nonresponders, and significantly lower at PTW12 than at baseline in responders (Figure 4 ). Compared to baseline, circulating levels of MIP1β were significantly lower at EOT and PTW12 in responders and at EOT only in relapsers (Figure 4 ). There was trend towards lower IL-18 levels at TW4 and EOT, with significantly lower levels at PTW12 compared to baseline in responders (Figure 4) . In addition, levels were also significantly lower in responders compared to relapsers at PTW12. At TW4, levels of IL-8 were significantly lower in responders compared to baseline (Figure 4 ). There were no other differences in IL-8 at other time points.
| DISCUSSION
There are limited data regarding peripheral ISG/IEG expression and circulating cytokine/chemokine profiling in the context of acute HCV infection in patients coinfected with HIV, especially in the context of the newer DAA-based therapies. It has been well established that intrahepatic ISG expression is associated with subsequent treatment outcome during IFN-based therapy for chronic HCV. 4, 6 In contrast, baseline peripheral ISG/IEG expression is not always associated with subsequent treatment outcome; however, changes in ISG expression in PBMCs during IFN-based therapy of chronic HCV mirror ontreatment changes in the intrahepatic compartment. 6 In addition, levels of several circulating chemokines/cytokines, in particular IP-10, have F I G U R E 4 Levels of circulating cytokines and chemokines at baseline and during/after treatment according to treatment outcome. TW4, treatment week 4; EOT, end of treatment; PTW12, post-treatment week 12; *P < .05, **P < .005, ***P < .0005 been associated with subsequent treatment response to IFN-based therapy. [7] [8] [9] 19 In the present study, 14 HIV-1-positive ART-treated pa- As previously reported in chronic HCV patients, we also observed a reduction in levels of several circulating chemokines/cytokines in the context of on-treatment viral suppression, several of which rebounded to pretreatment levels in relapsers but remained low in responders, 
